Dark Forest Capital Management LP Trims Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Dark Forest Capital Management LP cut its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 91.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,598 shares of the life sciences company’s stock after selling 137,495 shares during the period. Dark Forest Capital Management LP’s holdings in Integra LifeSciences were worth $396,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of IART. Capital Research Global Investors grew its position in Integra LifeSciences by 37.7% during the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after purchasing an additional 1,621,655 shares during the last quarter. Cooke & Bieler LP grew its holdings in shares of Integra LifeSciences by 12.4% during the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after buying an additional 388,710 shares during the last quarter. Champlain Investment Partners LLC increased its position in Integra LifeSciences by 10.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock valued at $95,289,000 after acquiring an additional 252,015 shares during the period. Dimensional Fund Advisors LP raised its stake in Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after acquiring an additional 12,766 shares during the last quarter. Finally, Madison Avenue Partners LP lifted its position in Integra LifeSciences by 8.0% during the 4th quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock worth $45,386,000 after acquiring an additional 77,489 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $17.87 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The stock has a market cap of $1.39 billion, a PE ratio of 35.74, a P/E/G ratio of 0.60 and a beta of 1.10. Integra LifeSciences Holdings Co. has a 1 year low of $16.96 and a 1 year high of $45.42. The stock has a fifty day moving average price of $21.33 and a 200 day moving average price of $27.20.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.71 EPS. Sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IART. Citigroup dropped their target price on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a report on Thursday, August 22nd. Truist Financial cut their price objective on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a research report on Tuesday, July 30th. BTIG Research lowered their target price on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a report on Wednesday, August 28th. Morgan Stanley raised their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Finally, JMP Securities cut their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and an average price target of $28.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.